Literature DB >> 27905415

Consistency in large pharmacogenomic studies.

Paul Geeleher1,2,3, Eric R Gamazon1,2,3, Cathal Seoighe4, Nancy J Cox1,2, R Stephanie Huang1.   

Abstract

Entities:  

Year:  2016        PMID： 27905415      PMCID： PMC6290674          DOI： 10.1038/nature19838

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  12 in total

1.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

2.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

Authors:  L R Kelland; S Y Sharp; P M Rogers; T G Myers; P Workman
Journal:  J Natl Cancer Inst       Date:  1999-11-17       Impact factor: 13.506

3.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Authors:  Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

4.  Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

Authors:  Christoph R Müller; Erik B Paulsen; Paul Noordhuis; Florence Pedeutour; Gunnar Saeter; Ola Myklebost
Journal:  Int J Cancer       Date:  2007-07-01       Impact factor: 7.396

5.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

6.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Crizotinib for the treatment of non-small-cell lung cancer.

Authors:  Andrew Timm; Jill M Kolesar
Journal:  Am J Health Syst Pharm       Date:  2013-06-01       Impact factor: 2.637

8.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

9.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

10.  Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.

Authors:  Steffen Falgreen; Karen Dybkær; Ken H Young; Zijun Y Xu-Monette; Tarec C El-Galaly; Maria Bach Laursen; Julie S Bødker; Malene K Kjeldsen; Alexander Schmitz; Mette Nyegaard; Hans Erik Johnsen; Martin Bøgsted
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430
View more
  18 in total

1.  Safikhani et al. reply.

Authors:  Zhaleh Safikhani; Nehme El-Hachem; Petr Smirnov; Mark Freeman; Anna Goldenberg; Nicolai J Birkbak; Andrew H Beck; Hugo J W L Aerts; John Quackenbush; Benjamin Haibe-Kains
Journal:  Nature       Date:  2016-11-30       Impact factor: 49.962

2.  Evaluating the consistency of large-scale pharmacogenomic studies.

Authors:  Raziur Rahman; Saugato Rahman Dhruba; Kevin Matlock; Carlos De-Niz; Souparno Ghosh; Ranadip Pal
Journal:  Brief Bioinform       Date:  2019-09-27       Impact factor: 11.622

3.  Revisiting inconsistency in large pharmacogenomic studies.

Authors:  Zhaleh Safikhani; Petr Smirnov; Mark Freeman; Nehme El-Hachem; Adrian She; Quevedo Rene; Anna Goldenberg; Nicolai J Birkbak; Christos Hatzis; Leming Shi; Andrew H Beck; Hugo J W L Aerts; John Quackenbush; Benjamin Haibe-Kains
Journal:  F1000Res       Date:  2016-09-16

4.  Patient-Derived In Vitro and In Vivo Models of Cancer.

Authors:  Sally E Claridge; Julie-Ann Cavallo; Benjamin D Hopkins
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

Review 6.  Computational estimation of quality and clinical relevance of cancer cell lines.

Authors:  Lucia Trastulla; Javad Noorbakhsh; Francisca Vazquez; James McFarland; Francesco Iorio
Journal:  Mol Syst Biol       Date:  2022-07       Impact factor: 13.068

Review 7.  Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models.

Authors:  Hossein Sharifi-Noghabi; Soheil Jahangiri-Tazehkand; Petr Smirnov; Casey Hon; Anthony Mammoliti; Sisira Kadambat Nair; Arvind Singh Mer; Martin Ester; Benjamin Haibe-Kains
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 13.994

8.  Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.

Authors:  Paul Geeleher; Zhenyu Zhang; Fan Wang; Robert F Gruener; Aritro Nath; Gladys Morrison; Steven Bhutra; Robert L Grossman; R Stephanie Huang
Journal:  Genome Res       Date:  2017-08-28       Impact factor: 9.043

9.  PATRI, a Genomics Data Integration Tool for Biomarker Discovery.

Authors:  G Ukmar; G E M Melloni; L Raddrizzani; P Rossi; S Di Bella; M R Pirchio; M Vescovi; A Leone; M Callari; M Cesarini; A Somaschini; G Della Vedova; M G Daidone; M Pettenella; A Isacchi; R Bosotti
Journal:  Biomed Res Int       Date:  2018-06-28       Impact factor: 3.411

10.  Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma.

Authors:  Eric R Gamazon; Matthew R Trendowski; Yujia Wen; Claudia Wing; Shannon M Delaney; Won Huh; Shan Wong; Nancy J Cox; M Eileen Dolan
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.